Randomized controlled trials: who fails run-in?

被引：0
|
作者：
Judy R. Rees
Leila A. Mott
Elizabeth L. Barry
John A. Baron
Jane C. Figueiredo
Douglas J. Robertson
Robert S. Bresalier
Janet L. Peacock
机构：
[1] Geisel School of Medicine at Dartmouth,Department of Epidemiology
[2] University of North Carolina School of Medicine,Department of Medicine
[3] University of Southern California,Department of Preventive Medicine, Keck School of Medicine
[4] White River Junction,Department of Medicine, VA Medical Center
[5] VT and Geisel School of Medicine at Dartmouth,Department of Gastroenterology, Hepatology and Nutrition
[6] The University of Texas MD Anderson Cancer Center,Division of Health and Social Care Research
[7] King’s College London,undefined
[8] London,undefined
[9] UK and NIHR Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College,undefined
来源：
Trials | / 17卷
关键词：
Randomized controlled trials; Run-in; Adherence; Generalizability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Letter: placebo run-in for IBS clinical trials - is it useful? Authors' reply
    Hamatani, Tatsuto
    Fukudo, Shin
    Nakada, Yosuke
    Inada, Hiroshi
    Kazumori, Kiyoyasu
    Miwa, Hiroto
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (07) : 1239 - 1240
  • [32] What is a run-in phase?
    Cipriani, Andrea
    Geddes, John R.
    EPIDEMIOLOGIA E PSICHIATRIA SOCIALE-AN INTERNATIONAL JOURNAL FOR EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2010, 19 (01): : 21 - 22
  • [33] Why Has a Run-In Period Been a Design Element in Most Landmark Clinical Trials? Analysis of the Critical Role of Run-In Periods in Drug Development
    Packer, Milton
    JOURNAL OF CARDIAC FAILURE, 2017, 23 (09) : 697 - 699
  • [34] LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS; THE RUN-IN STUDY
    Alton, E. W.
    Boyd, C.
    Cunningham, S.
    Davies, J. C.
    Hyde, S. C.
    Innes, J. A.
    Gill, D. R.
    Greening, A.
    Griesenbach, U.
    Higgins, T.
    Porteous, D. J.
    PEDIATRIC PULMONOLOGY, 2010, : 298 - 298
  • [35] LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS: THE RUN-IN STUDY
    Alton, E. W. F. W.
    Boyd, C.
    Cunningham, S.
    Davies, J. C.
    Hyde, S. C.
    Ianes, J. A.
    Gill, D. R.
    Greening, A.
    Griesenbach, U.
    Higgins, T.
    Porteous, D. J.
    THORAX, 2010, 65 : A11 - A11
  • [36] THE USE OF A RUN-IN BEFORE RANDOMIZATION
    LANG, JM
    CONTROLLED CLINICAL TRIALS, 1986, 7 (03): : 242 - 242
  • [37] Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation
    Lee, S
    Walker, JR
    Jakul, L
    Sexton, K
    DEPRESSION AND ANXIETY, 2004, 19 (01) : 10 - 19
  • [38] Break-in和Run-in
    李家柱
    机械制造, 1984, (02) : 40 - 40
  • [39] RUN-IN STRATEGY FOR ELECTRONIC ASSEMBLIES
    CAMERON, DB
    WALKER, R
    PROCEEDINGS ANNUAL RELIABILITY AND MAINTAINABILITY SYMPOSIUM, 1986, (SYM): : 262 - 266
  • [40] Use of a placebo run-in in clinical trials in patients with FM does not impact the response to pregabalin
    Pauer, L.
    Brown, P. Bhadra
    Clair, A.
    Scavone, J.
    JOURNAL OF PAIN, 2015, 16 (04): : S77 - S77
12345